Illinois Prescription Monitoring Program

Update - August 2025

Subscribe to follow us @ILPMP on YouTube

View as Webpage

The Illinois Prescription Monitoring Program (ILPMP) Advisory Committee will meet on Tuesday, September 16, 2025, from 12:00 to 1:30 p.m. CST. The meeting will bring together committee members, stakeholders, and partners to review program updates and discuss future initiatives.

Agenda highlights:

• Introduction of new Advisory Committee members
• Transition of ILPMP to the Division of Behavioral Health & Recovery
• Demonstration of the new ILPMP website and dashboard features
• Overview of the Academic Detailing Project
• Discussion on expanding authorized designee types for ILPMP access

The full agenda and meeting link for Webex can be found at Advisory Committee the week of September 8th.

The U.S. Food and Drug Administration (FDA) is requiring safety labeling changes to all opioid pain medications to better emphasize and explain the risks associated with their long-term use.

The labeling changes will include the following updates:   

• Clearer Risk Information: A summary of study results showing the estimated risks of addiction, misuse, and overdose during long-term use. 
• Dosing Warnings: Stronger warnings that higher doses come with greater risks, and that those risks remain over time. 
• Clarified Use Limits: Removing language which could be misinterpreted to support using opioid pain medications over indefinitely long duration 
• Treatment Guidance: Labels will reinforce that long-acting or extended-release opioids should only be considered when other treatments, including shorter-acting opioids, are inadequate. 
• Safe Discontinuation: A reminder not to stop opioids suddenly in patients who may be physically dependent, as it can cause serious harm. 
• Overdose Reversal Agents: Additional information on medicines that can reverse an opioid overdose. 
• Drug Interactions: Enhanced warning about combining opioids with other drugs that slow down the nervous system—now including gabapentinoids. 
• More Risks with Overdose: New information about toxic leukoencephalopathy—a serious brain condition that may occur after an overdose. 
• Digestive Health: Updates about opioid-related problems with the esophagus.  

The ILPMP is pleased to welcome Dr. Alma Ramic as the newest member of ILPMP Advisory Committee. Dr. Ramic received training in Psychiatry and Addiction Psychiatry/Medicine from University of Illinois, Chicago. She is currently serving as Medical Director of Addiction Services and Opiate Treatment Program, Hines Veterans Affairs (VA), Assistant Professor of Psychiatry at Loyola University Medical School and Program Site Director for Addiction Medicine/Psychiatry at Hines VA.



Outside of Department of VA, Dr. Ramic has worked at Cook County Department of Correction for over a decade.

We are thrilled to welcome her to the ILPMP Advisory Committee and look forward to the valuable insights and expertise she will bring to our work.

Pharmacy Data Submitter Reminder - Correcting Errors on the Illinois RxSubmit Portal

The ILPMP is reminding its retail pharmacies, pharmacists, and dispensing practitioners of the requirements for error and warning corrections and updating submitter information within Illinois RxSubmit.

As a pharmacy or dispensing practitioner, you may be contacted by our team regarding unresolved errors or to confirm pharmacy contact(s) via email or phone. This outreach is an effort to minimize wrongful non-compliance emails, improve communication and educational efforts, and increase data-cleansing. For initial education, review our updated Illinois Data Submitter Guide (sections 7.4: Processed File with Error and 11: Organization Management).

Errors and Warnings:

Error = prescription does not display on patient profile

Warning = displays on patient profile but information is incorrect/unavailable

Based on your role, you must either inform someone or correct the error. Submitter emails will receive a “file process status report” which shows the number of accepted, errored, warning, duplicate, and voided prescriptions.

See the specific requirements below:

• Prescriber has 7 calendar days to inform the dispensing pharmacy/practitioner of missing or inaccurate prescriptions.
• Dispensing pharmacy/practitioner has 7 calendar days of being made aware of the missing or inaccurate prescriptions to correct.

Updating Submitters Information:

To ensure only current submitters have access, please update all submitter information as changes occur.

New Submitters:

• Register for an Illinois RxSubmit account
• Link new account with previous submitter account (see section 11)

Old Submitters:

• Assist new submitter in linking account (see section 11)

Updating sFTP:

• Contact ILPMP or Data Submission Vendor, LogiCoy, to update sFTP submission email

Deactivating accounts:

• Email ILPMP and LogiCoy to inform that the previous submitters account can be deactivated

Contact our team at dhs.dbhr.pharmacycompliance@illinois.gov with questions related to error and warning corrections or to update submitter information. To open a ticket with our Data Submission Vendor please email ilpmp@logicoy.com.

Prescribing Tip - Urine drug testing is a vital component of any opioid risk mitigation program. This short animated video briefly introduces these tests and their place in practice. Brought to you by the Southern Illinois University Edwardsville School of Pharmacy and the Illinois Prescription Monitoring Program.

The ILPMP is announcing an important upcoming change regarding the reporting of controlled substances and current drugs of interest. By Illinois law, retail pharmacies and dispensing practitioners are required to electronically transmit a daily dispensing report no later than the end of the business day on which a controlled substance II-V or drug of interest is dispensed to the patient.

Effective July 1, 2025, the ILPMP began transitioning to the American Society for Automation in Pharmacy (ASAP) Version 5.0 format with a transition deadline of December 16, 2025. Pharmacies and software vendors should work proactively to update their systems and ensure compatibility with the new reporting format by the mandatory deadline.

This change is part of our ongoing commitment to improve data accuracy, enhance reporting capabilities, and align with national standards for prescription drug monitoring programs (PDMPs).

Key Dates:

• July 1, 2025 - ASAP testing window opens
• December 16, 2025 - ASAP format becomes mandatory for all data submitters

Drugs of Interest List revised to include drug classes

As part of this update, the ILPMP is also transitioning to a more generalized approach by categorizing drugs by class. This change allows for the automatic inclusion of new drugs approved by the Food and Drug Administration (FDA) within those classes. Pharmacies and dispensing physicians will be responsible for maintaining an up-to-date list of drugs within the specified classes to ensure accurate reporting.

What This Means for You

• **** Please contact LogiCoy via e-mail at ilpmp@logicoy.com to setup a test submission and obtain the checklist for the new ASAP 5.0 format. No files should be submitted in new format until this is complete. ****

• Current submissions in the ASAP 4.2A format will continue to be accepted during the transition period.

• ASAP Version 5.0 is located on ILPMP.org / About Us / Pharmacy Reporting / Illinois Data Submitter Guide

#OverdoseAwarenessWeek is a reminder that we all have a role to play in preventing overdoses. Learn how to recognize the signs of overdose, how to use naloxone & nalmefene and support people in recovery: samhsa.gov/end-overdose

Working together, we can make Every Day Take Back Day. Scan the QR code or click image below to view Year-Round Drop Off locations for prescription drugs.

Newly Released, FREE, Continuing Education Available for Pharmacists and Pharmacy Technicians on the Importance of PMP Data Integrity

Take advantage of this free ACPE accredited educational opportunity providing 1 hour of continuing education for pharmacists and pharmacy technicians. This program, developed in partnership with NASCSA and 12 prescription monitoring program (PMP) administrators, analyzes the importance and value of complete, accurate data reported by dispensers to PMPs and assesses the impact of intentional or non-intentional data entry errors and data omissions on patient safety. It also discusses the downstream impacts of pharmacy-reported PMP data on clinical decision-making processes and helps pharmacy staff identify and implement changes that can be made in their practice setting to improve PMP data integrity.

Visit https://ce.talemhealth.com/a/MWEORC



If you received credit for this CE prior to 10/22/24, you are still able to retake the CE and receive credit.  

Navigating Pain Management, Safe Opioid Prescribing, and Opioid Use Disorder

A three-hour program designed to meet the educational needs for physicians, nurses, and pharmacists. The program is accredited in 6, 30-minute modules.

If you have questions about the information that appears in this update or suggestions for future content, please email dhs.pmp@illinois.gov. Visit www.ilpmp.org for more information.

The Illinois Prescription Monitoring Program (ILPMP) is an electronic database that collects, tracks, and stores reported dispensing data on Schedule II-V controlled substances, selected drugs of interest, and other health information. The Illinois Department of Human Services oversees the ILPMP, authorized by the Illinois Controlled Substances Act (720 ILCS 570/316). The ILPMP adheres to HIPAA and all access, disclosure, and confidentiality provisions of Illinois Law.